From HandWiki - Reading time: 3 min
| Clinical data | |
|---|---|
| Other names | Doxyfluridine; doxifluridine; 5'-deoxy-5-fluorouridine; 5'-deoxy-5'-fluorouridine; 5'-fluoro-5'-deoxyuridine; 5'-dFUrd; 5'-DFUR; Furtulon; Ro 21-9738 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C9H11FN2O5 |
| Molar mass | 246.194 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Doxifluridine is a second generation nucleoside analog prodrug developed by Roche and used as a cytostatic agent in chemotherapy in several Asian countries including China and South Korea.[1] Doxifluridine is not FDA-approved for use in the USA. It is currently being evaluated in several clinical trials as a stand-alone or combination therapy treatment.
5-fluorouracil (5-FU), the nucleobase of doxifluridine, is currently an FDA-approved antimetabolite.[2] 5-FU is normally administered intravenously to prevent its degradation by dihydropyrimidine dehydrogenase in the gut wall. Doxifluridine (5´-deoxy-5-fluorouridine) is a fluoropyrimidine derivative of 5-FU, thus a second-generation nucleoside prodrug. Doxifluridine was designed to improve oral bioavailability in order to avoid dihydropyrimidine dehydrogenase degradation in the digestive system.[3]
Within a cell, pyrimidine nucleoside phosphorylase or thymidine phosphorylase can metabolize doxifluridine into 5-FU.[4][5] It is also a metabolite of capecitabine.[4] High levels of pyrimidine-nucleoside phosphorylase and thymidine phosphorylase are expressed in esophageal, breast, cervical, pancreatic, and hepatic cancers.[6][7] Liberation of 5-FU is the active metabolite and leads to inhibition of DNA synthesis and cell death.
High thymidine phosphorylase expression is also found in the human intestinal tract, resulting in dose-limiting toxicity (diarrhea) in some individuals.[8]
The most frequent adverse effects for doxifluridine were neurotoxicity and mucositis.[citation needed]
Doxifluridine is sold under many brand names:[9]
| Brand name | Company | Country |
|---|---|---|
| Didox[10] | Shin Poong Pharm. Co., Ltd. | South Korea |
| Doxyfluridine[9] | Kwang Dong | |
| Doxifluridine cap | Myungmoon Pharma Co. Ltd. | |
| Ai Feng[9] | Hengrui | China and Japan |
| Doxifluridine[9] | XinShiDai Pharmaceutical | |
| Furtulon[9] | Roche, Chugai | |
| Ke Fu[9] | Zhaohui | |
| Ke Tuo[9] | Southwest | |
| Qi Nuo Bi Tong[9] | Wanjie High-Tech | |
| Shu Qi[9] | Team | |
| Tan Nuo[9] | Xinchang Medicine & Chemical Co Ltd | |
| Yi Di An[9] | Pacific |